Licensing & partnership
Emergent wins up to $22.3M US military order for BioThrax anthrax vaccine
Emergent BioSolutions had an option exercised under an existing indefinite-quantity contract, worth as much as $22.3 million, covering BioThrax deliveries to the US Department of War. The first shipment, valued near $7.4 million, starts this year and the rest follows in 2027. The vaccine is used across the military as pre-exposure protection against anthrax.
Written by Gosset from public sources. Source types: Press release. Sources are available to Gosset users. Log in to see them.